Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

December 31, 2006

Study Completion Date

October 31, 2007

Conditions
SchizophreniaSchizoaffective DisorderTardive DyskinesiaInsulin ResistanceObesity
Interventions
DRUG

Panax Ginseng

The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.

Trial Locations (4)

Unknown

Queen's University, Kingston

Northern Ontario Medical School, Thunder Bay

N5P 3V9

Regional Mental Health Care London, St. Thomas

HA13UJ

Northwick Park Hospital, Harrow

All Listed Sponsors
collaborator

Queen's University

OTHER

collaborator

Northern Ontario School of Medicine

OTHER

collaborator

Imperial College London

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT00401089 - Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia | Biotech Hunter | Biotech Hunter